organization · Reporting owner
Biohaven Pharmaceutical Holding Co Ltd.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Biohaven Ltd.BHVN · Entity 4379 | 10% owner | October 03, 2022 | October 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Biohaven Ltd.
Report date October 03, 2022 · Filed October 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-10-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-10-03 · Other · Acquired 35,839,857 · Balance 35,839,857 F1: On October 3, 2022, in connection with the distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") of the outstanding common shares of the Issuer ("Common Shares") pursuant to the Separation and Distribution Agreement, dated May 9, 2022, between RemainCo and the Issuer, the Issuer issued to RemainCo 35,839,857 Common Shares (the "Issuance"). Row 2 · 2022-10-03 · Other · Disposed 35,839,857 · Balance 0 F2: On October 3, 2022, immediately following the Issuance, all of the outstanding common shares of the Issuer held by RemainCo were distributed by way of a pro rata distribution to RemainCo's shareholders (the "Distribution"). As a result of the Distribution, RemainCo no longer beneficially owns any common shares of the Issuer and consequently is no longer subject to the requirements of Section 16 of the Exchange Act with respect to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 3, 2022, in connection with the distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") of the outstanding common shares of the Issuer ("Common Shares") pursuant to the Separation and Distribution Agreement, dated May 9, 2022, between RemainCo and the Issuer, the Issuer issued to RemainCo 35,839,857 Common Shares (the "Issuance").
F2: On October 3, 2022, immediately following the Issuance, all of the outstanding common shares of the Issuer held by RemainCo were distributed by way of a pro rata distribution to RemainCo's shareholders (the "Distribution"). As a result of the Distribution, RemainCo no longer beneficially owns any common shares of the Issuer and consequently is no longer subject to the requirements of Section 16 of the Exchange Act with respect to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 03, 2022 Filed Oct 5, 2022 21:40 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherCommon Shares | 35,839,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007082 · primarydocument.xml · nonDerivative · entry 2 Biohaven Pharmaceutical Holding Co Ltd. · CIK 0001689813 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: On October 3, 2022, immediately following the Issuance, all of the outstanding common shares of the Issuer held by RemainCo were distributed by way of a pro rata distribution to RemainCo's shareholders (the "Distribution"). As a result of the Distribution, RemainCo no longer beneficially owns any common shares of the Issuer and consequently is no longer subject to the requirements of Section 16 of the Exchange Act with respect to the Issuer. F2 · shares: On October 3, 2022, immediately following the Issuance, all of the outstanding common shares of the Issuer held by RemainCo were distributed by way of a pro rata distribution to RemainCo's shareholders (the "Distribution"). As a result of the Distribution, RemainCo no longer beneficially owns any common shares of the Issuer and consequently is no longer subject to the requirements of Section 16 of the Exchange Act with respect to the Issuer. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:40 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherCommon Shares | 35,839,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007082 · primarydocument.xml · nonDerivative · entry 1 Biohaven Pharmaceutical Holding Co Ltd. · CIK 0001689813 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,839,857 F1 · kind: On October 3, 2022, in connection with the distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") of the outstanding common shares of the Issuer ("Common Shares") pursuant to the Separation and Distribution Agreement, dated May 9, 2022, between RemainCo and the Issuer, the Issuer issued to RemainCo 35,839,857 Common Shares (the "Issuance"). F1 · shares: On October 3, 2022, in connection with the distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") of the outstanding common shares of the Issuer ("Common Shares") pursuant to the Separation and Distribution Agreement, dated May 9, 2022, between RemainCo and the Issuer, the Issuer issued to RemainCo 35,839,857 Common Shares (the "Issuance"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.